Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFIRINOX for borderline or locally advanced unresectable pancreatic ductal adenocarcinoma
jRCT1051190099Phase 2Recruiting
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FOLFIRINOX in pancreatic adenocarcinoma (PDAC). Primary endpoint: R0 resectability. Started Jun 2020; status: recruiting.
02
Drugs
FOLFIRINOX
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT1051190099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051190099.